2-(1-octynyl)adenosine has been researched along with atl 313 in 1 studies
| Studies (2-(1-octynyl)adenosine) | Trials (2-(1-octynyl)adenosine) | Recent Studies (post-2010) (2-(1-octynyl)adenosine) | Studies (atl 313) | Trials (atl 313) | Recent Studies (post-2010) (atl 313) |
|---|---|---|---|---|---|
| 23 | 0 | 3 | 26 | 0 | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donegan, RK; Lieberman, RL | 1 |
1 review(s) available for 2-(1-octynyl)adenosine and atl 313
| Article | Year |
|---|---|
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
Topics: Adrenergic Agonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Animals; Drug Discovery; Glaucoma; Humans; Ligands; Protein Kinase Inhibitors; rho-Associated Kinases; Sympathomimetics | 2016 |